Chimerix Inc
NASDAQ:CMRX

  • LAST PRICE
    0.9875
  • TODAY'S CHANGE (%)
    0.0177 (1.8251%)
  • Bid / Lots
    0.9900/ 8
  • Ask / Lots
    1.0000/ 1
  • Open / Previous Close
    0.9600 / 0.9698
  • Day Range
    0.9500
    0.9999
  • 52 Week Range
    0.8800
    1.5700
  • Volume
    92,214

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 1, 2024

      Show headlines and story abstract

    • 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
      Companies Mentioned: CMRX

    • 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
      Companies Mentioned: CMRX
      Other long-term assets 260 301 -------- --------- Total assets $ 194,042 $ 212,774 ======== ========= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,823 $ 2,851 Accrued liabilities 15,112 15,592 Total current liabilities 18,935 18,443 Line of credit commitment fee - 125 Lease-related obligations 1,005 1,177 -------- --------- Total liabilities 19,940 19,745 Stockholders' equity: Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and - - Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 89,629,902 and 88,929,300 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 90 89 Additional paid-in capital 991,583 988,457 Accumulated other comprehensive (gain) loss, net (178) 7 Accumulated deficit (817,393) (795,524) -------- --------- Total stockholders' equity 174,102 193,029 -------- --------- Total liabilities and stockholders' equity $ 194,042 $ 212,774 ======== ========= CHIMERIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, ----------------------------------- 2024 2023 Revenues: Contract and grant revenue $ - $ 234 Licensing revenue - 49 Total revenues - 283 Operating expenses: Research and development 18,844 18,822 General and administrative 5,546 5,679 Total operating expenses 24,390 24,501 ------------ ------------ Loss from operations (24,390) (24,218) Other income: Interest income and other, net 2,521 2,846 Net loss (21,869) (21,372) Other comprehensive (loss) income: Unrealized (loss) gain on debt investments, net (185) 106 ------------ ------------ Comprehensive loss $ (22,054) $ (21,266) ============ ============ Per share information: Net loss, basic and diluted $ (0.25) $ (0.24) Weighted-average shares outstanding, basic and diluted 89,259,106 88,294,624

    • 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
      Companies Mentioned: CMRX
      Other long-term assets 260 301 -------- --------- Total assets $ 194,042 $ 212,774 ======== ========= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,823 $ 2,851 Accrued liabilities 15,112 15,592 Total current liabilities 18,935 18,443 Line of credit commitment fee - 125 Lease-related obligations 1,005 1,177 -------- --------- Total liabilities 19,940 19,745 Stockholders' equity: Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and - - Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 89,629,902 and 88,929,300 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 90 89 Additional paid-in capital 991,583 988,457 Accumulated other comprehensive (gain) loss, net (178) 7 Accumulated deficit (817,393) (795,524) -------- --------- Total stockholders' equity 174,102 193,029 -------- --------- Total liabilities and stockholders' equity $ 194,042 $ 212,774 ======== ========= CHIMERIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, ----------------------------------- 2024 2023 Revenues: Contract and grant revenue $ - $ 234 Licensing revenue - 49 Total revenues - 283 Operating expenses: Research and development 18,844 18,822 General and administrative 5,546 5,679 Total operating expenses 24,390 24,501 ------------ ------------ Loss from operations (24,390) (24,218) Other income: Interest income and other, net 2,521 2,846 Net loss (21,869) (21,372) Other comprehensive (loss) income: Unrealized (loss) gain on debt investments, net (185) 106 ------------ ------------ Comprehensive loss $ (22,054) $ (21,266) ============ ============ Per share information: Net loss, basic and diluted $ (0.25) $ (0.24) Weighted-average shares outstanding, basic and diluted 89,259,106 88,294,624

  • Apr 24, 2024

Peers Headlines